SCO-101 works in synergy with the chemotherapy drug docetaxel in drug resistant cancer cells
Scandion Oncology A/S (“Scandion Oncology”) has published that combining SCO-101 and the chemotherapy drug docetaxel, which is used in the treatment of several types of cancer, results in synergy. Based on modelling of preclinical data with docetaxel resistant cancer cells, Scandion Oncology has published that SCO-101 significantly increases the potency of docetaxel (docetaxel belongs to the group of taxane chemotherapy). Furthermore, the results provided key information regarding promising dose ratios and dose levels for future clinical studies when using the combination of SCO-101 and